biotech / news / / Seeking Alpha
Pfizer begins late-stage trial for new pneumococcal shot in infants after strong Phase 2 data.
Pfizer has initiated a Phase 3 trial for its 25-valent pneumococcal vaccine in infants.
KEY POINTS
- The new 25vPnC vaccine outperformed Prevnar 20 in Phase 2 trials for infants.
- 25vPnC targets more pneumococcal strains than the currently approved Prevnar 20 vaccine.
- This Phase 3 study marks a significant step toward potentially replacing or supplementing Prevnar 20.
COMPANIES
Summarized by Newsio from Seeking Alpha. How we summarize →